# US 10,870,692 B2 · Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,870,692 B2
- Document ID: US10870692B2
- Status: Granted
- Kind: B2
- Application number: 16/265,437
- Filed: 2019-02-01
- Published: 2019-07-04
- Granted: 2020-12-22
- Earliest claimed: 2006-08-02
- Assignees: The UAB Research Foundation
- Applicants: The Uab Research Foundation
- Inventors: Max D. Cooper; Brantley R. Herrin; Matthew N. Alder
- Web page: https://patentgrep.com/patent/US10870692B2

## CPC

- C07K 16/1278: Bacillus (G)
- A61P 31/12: Antivirals
- A61P 31/16: for influenza or rhinoviruses
- A61P 31/18: for HIV
- C07K 16/108: Orthomyxoviridae (F), e.g. influenza virus
- C07K 16/1145: {Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site}
- C07K 16/34: against blood group antigens
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C07K 2317/20: characterized by taxonomic origin
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/35: Valency
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are compositions and methods related to variable lymphocyte receptors (VLRs). More particularly, disclosed are a variety of antigen specific polypeptides, including soluble, monoclonal, and multivalent forms, as well as methods of using the polypeptides, antibodies that bind the antigen specific polypeptides, and nucleic acids, vectors and expression systems that encode the polypeptides. Antigen specific polypeptides that selectively bind pathogens, like anthrax, and carbohydrates, like blood group determinants, are specifically disclosed.

## Claims

### Claim 1

A purified multimer comprising a plurality of soluble, monoclonal antigen specific polypeptides, wherein each antigen specific polypeptide comprises
a. a N-terminal leucine rich repeat (LRRNT),
b. one or more internal leucine rich repeats (LRRs),
c. a C-terminal leucine rich repeat (LRCCT), and
d. a connecting peptide, wherein the connecting peptide comprises an alpha helix.

### Claim 2 (depends on 1)

The multimer of claim 1, comprising up to ten antigen specific polypeptides.

### Claim 3 (depends on 1)

The multimer of claim 1, wherein the antigen specific polypeptides bind a target protein.

### Claim 4 (depends on 1)

The multimer of claim 1, wherein the antigen specific polypeptides bind a target carbohydrate.

### Claim 5 (depends on 1)

The multimer of claim 1, wherein the antigen specific polypeptides bind a target pathogen.

### Claim 6 (depends on 2)

The multimer of claim 2, wherein the multimer is a multivalent multimer that binds to more than one target.